Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Delft – page 77

1 232 clinical trials in Delft, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Delft at a glance
1 232
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 232 trials in Delft

Open in trial search

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Muscular dystrophy

Not recruiting

Study on the Effects of Ribitol (BBP-418) in Patients with Limb Girdle Muscular Dystrophy Type 2I

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Hormone-dependent prostate cancer

Not recruiting

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:LEO PHARMA A/S

Prostate cancer metastatic

Not recruiting

Study on the Effectiveness and Safety of Apalutamide, Abiraterone Acetate, and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Not recruiting

Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Not recruiting

Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

B-cell lymphoma refractory

Not recruiting

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Chronic kidney disease

Not recruiting

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Non-small cell lung cancer

Not recruiting

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Dimenhydrinate
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Delft

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular disease management and prevention, including studies of novel treatments for atherosclerotic cardiovascular disease and innovative therapies targeting lipoprotein reduction.

  • Lipid Management Studies
  • Cardiovascular Risk Prevention
  • Major Adverse Cardiac Events

Research exploring both established and experimental treatments to reduce cardiovascular complications and improve patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, with significant focus on prostate cancer, breast cancer, and blood cancers including chronic lymphocytic leukemia.

  • Advanced Imaging Techniques
  • Targeted Therapies
  • Treatment Combinations

Innovative approaches combining established treatments with novel therapeutic agents to enhance treatment effectiveness.

03 Women's Health

Studies addressing various aspects of women's health, including infertility treatments and management of uterine fibroids.

  • Reproductive Health
  • Gynecological Conditions
  • Quality of Life Studies

Research comparing different treatment modalities and their impact on patient outcomes and quality of life.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.